Nucleoside reverse transcriptase inhibitors (NRTIs) for chronic hepatitis BReferencesCitationsSherman M, et al. (2007). Management of chronic
hepatitis B: Consensus guidelines. Canadian Journal of
Gastroenterology, 21(Suppl C): 5C–24C. Lok ASF, McMahon BJ (2007). Chronic hepatitis B.
Hepatology, 45(2): 507–539. Hadziyannis SJ, et al. (2003). Adefovir dipivoxil for
the treatment of hepatitis B e antigen-negative chronic hepatitis B.
New England Journal of Medicine, 348(9):
800–807. Lai CL, et al. (2002) Entecavir is superior to
lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis
B infection. Gastroenterology, 123(6):
2135–2140. de Man RA, et. al. (2001) Safety and efficacy of oral
entecavir given for 28 days in patients with chronic hepatitis B virus
infection. Hepatology, 34(3): 578–82. Hadziyannis, SJ, et al. (2005). Long-term therapy with
adefovir dipivoxil for HBeAg-negative chronic hepatitis B. New
England Journal of Medicine, 352(26): 2673–2681. Han SH (2005). Telbivudine: A new nucleoside analogue
for the treatment of chronic hepatitis B. Expert Opinion on
Investigational Drugs, 14(4): 511–519. Chan HLY, et al. (2005). A randomized, controlled
trial of combination therapy for chronic hepatitis B: Comparing pegylated
interferon alfa-2b and lamivudine with lamivudine alone. Annals
of Internal Medicine, 142(4): 240–250. Janssen H (2005). Pegylated interferon alfa-2b alone
or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A
randomised trial. Lancet, 365(9454):
123–129.
| | Author: | Douglas Dana Maria G. Essig, MS, ELS | Last Updated: February 8, 2008 | | Medical Review: | Anne C. Poinier, MD - Internal Medicine Kathleen Romito, MD - Family Medicine W. Thomas London, MD - Hepatology Jerome B. Simon, MD, FRCPC, FACP - Gastroenterology | © 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
| 
| |
| |